doi: 10.1038/458394b.
Bills target biosimilar drugs
- PMID: 19325595
- DOI: 10.1038/458394b
Item in Clipboard
Bills target biosimilar drugs
Nature.
.
No abstract available
Similar articles
-
'Biosimilar' drugs poised to penetrate market.Nature. 2010 Nov 4;468(7320):18-9. doi: 10.1038/468018a. Nature. 2010. PMID: 21048737 No abstract available.
-
US biotech prepares to fight generic biologics.Nat Biotechnol. 2002 Apr;20(4):322. doi: 10.1038/nbt0402-322a. Nat Biotechnol. 2002. PMID: 11923820 No abstract available.
-
SuperGenerics: a better alternative for biogenerics.Drug Discov Today. 2005 Apr 15;10(8):533-5. doi: 10.1016/S1359-6446(05)03410-0. Drug Discov Today. 2005. PMID: 15837591 No abstract available.
-
[Similarity of biotechnology-derived drugs: regulatory framework and specificity].Ann Pharm Fr. 2008 Aug;66(4):206-11. doi: 10.1016/j.pharma.2008.07.008. Epub 2008 Sep 9. Ann Pharm Fr. 2008. PMID: 18847566 Review. French.
-
Biosimilars: opportunity or cause for concern?J Pharm Pharm Sci. 2007;10(3):405-10. J Pharm Pharm Sci. 2007. PMID: 17727803 Review.
Cited by
-
Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases.Drug Saf. 2013 Aug;36(8):617-25. doi: 10.1007/s40264-013-0073-3. Drug Saf. 2013. PMID: 23771794
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
